Want to see SE:VIVE full AI Analyst Report?
VIVE Stock Chart & Stats
kr0.08
>-kr0.01(-0.59%)
At close: 4:00 PM EST
kr0.08
>-kr0.01(-0.59%)
Day’s Range― - ―
52-Week Rangekr7.00 - kr23.81
Previous CloseN/A
Volume772.68K
Average Volume (3M)9.02K
Market Cap
kr97.32M
Enterprise Valuekr70.59
Total Cash (Recent Filing)kr23.51M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding11,071,369
10 Day Avg. Volume10,079
30 Day Avg. Volume9,018
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio-165.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Equity CushionThe substantial equity cushion and currently debt-free balance sheet provide financial resilience for a development-stage biotechnology company. Low leverage reduces interest and refinancing pressure, preserving flexibility to fund oncology programs and absorb continued operating volatility over the next several quarters.
Improving Loss TrendAlthough profitability remains negative, the material reduction in losses versus earlier periods indicates improving cost discipline or operating efficiency. If sustained, this trajectory could extend the company’s financial runway and reduce the scale of funding required while its development programs advance.
Oncology Development FocusA focused oncology strategy gives Vivesto a defined therapeutic area and allows its drug candidates and delivery approaches to be developed around clinically important efficacy and tolerability needs. This specialization can support coherent resource allocation across its pipeline and future partnering efforts.
Bears Say
Minimal Revenue BaseEffectively zero revenue means Vivesto has not yet demonstrated recurring commercial demand or self-funded operating scale. The company therefore remains dependent on advancing development assets toward approval, licensing transactions, or future financing rather than relying on established product income.
Persistent Net LossesPersistent net losses weaken retained resources and make the business model dependent on future operational progress or external capital. Continued losses can gradually erode the reported equity cushion, limiting strategic flexibility unless development programs begin producing revenue or other funding proceeds.
Ongoing Cash BurnNegative operating and free cash flow show that current activities consume cash rather than generate it. Even though burn has improved from earlier years, continued outflows leave Vivesto dependent on available liquidity or financing to sustain research, development, and corporate operations.
Vivesto AB News
VIVE FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was kr7.00 and its highest was kr23.81 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is kr97.32M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is Nov 12, 2026 which is in 46 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on Aug 13, 2026. The company reported -kr0.757 earnings per share for the quarter.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 11,071,369 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -kr0.757 in its last earnings report. Following the earnings report the stock price went up 3.691%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in SE:VIVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
SpectraCure AB
―
Nanologica AB
―
Spago Nanomedical AB
―
Nanexa AB
―